BPC June 16 updates: PRTK spikes up 23% after hours following Phase 3 data. SUPN PDUFA delay + updates for AERI BLPH CCXI CRBP KPTI ONCS

Jun 17, 2016 No Comments

Updates to the Company Pipeline Database for June 16, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AERI 18.51 Rhopressa Glaucoma NDA filing NDA filing due 3Q 2016 BLPH 1.98 INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrolment June 2016 CCXI 4.80 CCX168 Associated vasculitis […]

Read more

BPC June 15 updates: ENDP Adcom scheduled for fall + FLKS initiates Phase 2 MS trial + CTIX update.

Jun 16, 2016 No Comments

Updates to the Company Pipeline Database for June 15, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ENDP 16.82 OPANA ER Management of pain PDUFA Advisory Committee Meeting planned for fall of 2016. PDUFA July 29 2016 will not be met. FLKS 11.22 FLX-787 Multiple Sclerosis Phase 2 Phase 2 […]

Read more

BPC June 14 updates: INFI slides 70% following Phase 2 data release + BPMX update

Jun 15, 2016 No Comments

Updates to the Company Pipeline Database for June 14, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BPMX 0.77 BPX-03 Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia Phase 3 Phase 3 to be initiated in 2017 INFI 1.36 Duvelisib (IPI-145) DYNAMO Indolent […]

Read more

BPC June 13 updates: KMPH issued CRL. MRNS and RVNC both fail Phase 3 trials + updates for ARGS ARIA FCSC MESO ONCE VICL

Jun 14, 2016 No Comments

Updates to the Company Pipeline Database for June 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARGS 5.95 AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Third interim analysis June 2016. Overall survival analysis due 1H 2017 ARIA 8.20 Iclusig (ponatinib) – OPTIC-2L Cancer – second line […]

Read more

BPC June 9 updates: KMPH PDUFA delay. SPHS rockets 125% after hours following data release + updates for ALNY ARWR CDTX IRWD OTIC VRX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 65.41 ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016 ARWR 5.99 ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Phase […]

Read more

BPC June 8 updates: FCSC Phase 2 trial fail. TENX Levosimendan data due 4Q. TRVN Phase 3 Oliceridine data due 1Q + updates for ADXS SCYX TGTX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 8, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADXS 9.01 Axalimogene filolisbac (FAWCETT) Anal cancer Phase 2 Phase 2 initiated June 2016 FCSC 1.26 azficel-T Chronic Dysphonia Phase 2 Phase 2 endpoints not met – June 2016 SCYX 4.11 SCY-078 Vulvovaginal […]

Read more

BPC June 7 updates: CYTR data delayed until July. CATB falls on disappointing data. CLCD Phase 3 data due 3Q + updates for ALDX CYTX IMUC RGLS SAGE ZGNX

Jun 08, 2016 No Comments

Updates to the Company Pipeline Database for June 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDX 5.75 NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 2 data due 3Q 2016 CATB 6.85 CAT-2054 Hypercholesterolemia Phase 2a Phase 2a did not meet primary endpoint – June 2016 CLCD 7.16 […]

Read more

BPC June 6 updates: DNAI OCUL plummet following data. ADMP issued CRL. MSTX delays Phase 3 Sickle cell disease data + updates for ADXS AEZS ARRY CARA GLYC IMMU ONTY

Jun 07, 2016 No Comments

Updates to the Company Pipeline Database for June 6, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADMP 4.09 Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. CRL CRL issued March 27 2015. NDA resubmitted. CRL issued again June 6, 2016. Intends to submit more data 2H 2016 ADXS […]

Read more

BPC June 2 updates: AKAO CORT FWP MBRX MDVN SMMT

Jun 03, 2016 No Comments

Updates to the Company Pipeline Database for June 2, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AKAO 3.61 Plazomicin – EPIC trial Complicated urinary tract infections (cUTI) Phase 3 Phase 3 top-line results due 1Q 2017 CORT 6.25 Mifepristone in combination with eribulin Cancer – triple-negative breast cancer […]

Read more